Business Context and Reporting Period
This Form 8-K is filed by OncoGenex Pharmaceuticals, Inc. (noting a discrepancy with the metadata company name "ACHIEVE LIFE SCIENCES, INC.") for the reporting date of February 27, 2017. The filing addresses a regulatory notice regarding the continued listing of the Company's common stock on The NASDAQ Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on compliance with listing standards rather than financial performance metrics.
Material Changes
The primary material event is the Company's failure to regain compliance with NASDAQ Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. Although the initial 180-day compliance period ended on February 21, 2017, without the stock meeting the price requirement, NASDAQ granted the Company an additional 180-day grace period.
Guidance, Outlook, and Risks
- Compliance Plan: The Company intends to cure the deficiency during the second compliance period by effecting a reverse stock split of its common stock.
- Deadline: The new deadline to regain compliance is August 21, 2017.
- Delisting Risk: If the Company fails to meet the $1.00 minimum bid price requirement by August 21, 2017, NASDAQ will notify the Company that its stock is subject to delisting.
- Appeal Rights: In the event of a delisting notice, the Company retains the right to appeal the determination to a NASDAQ Listing Qualifications Panel and request a hearing.
Investor Verification Checklist
- Verify the current status of the proposed reverse stock split and whether it has been approved by shareholders.
- Monitor the daily closing bid price of the Company's common stock to ensure it meets the $1.00 threshold for ten consecutive business days before August 21, 2017.
- Confirm the Company's continued compliance with other NASDAQ listing requirements, specifically the market value of publicly held shares.
- Review any subsequent filings for updates on the delisting appeal process if the August 2017 deadline is missed.